Thomas, McNerney &a; Partners

Thomas, McNerney &a; Partners is a health care venture capital firm with approximately $600 million under management focused on investing in

Business Model:

Revenue: $14.3M

Employees: 11-50

Rankings

Detailed Thomas, McNerney &a; Partners Information

Geographic Data

Thomas, McNerney &a; Partners headquarters map

Address: 263 Tresser Blvd 9th Floor

City: Stamford

State: CT

Zip: 06901

Country: US

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$0

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

Thomas, McNerney &a; Partners is a health care venture capital firm with approximately $600 million under management focused on investing in life science and medical technology companies. The firm targets investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors as well as in other areas utilizing medical technology innovation. Companies developing therapeutic products for life threatening or costly, chronic conditions are of particular interest. Thomas, McNerney &a; Partners invests in companies at all stages of their development. In addition to helping entrepreneurs launch companies with seed and early stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. The partnership also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies as well as recapitalizations.

Contact Phone:
+12039782010

Contact Email:

Announced Date Company Transaction Money Raised
3/2017 VertiFlex Equity 45.3M
10/2009 Quinnova Pharmaceuticals Series B 17.4M
12/2006 Softscope Medical Technologies Series A 4M
7/2010 Zogenix Venture Round 0
4/2012 Tioga Pharmaceuticals Series B 10M
2/2010 Altair Therapeutics Series B 17M
11/2007 Tranzyme Venture Round 20M
8/2003 Coley Pharmaceutical Group Series F 30M
2/2004 Clarus Therapeutics Series A 2.5M
3/2006 Clarus Therapeutics Series B -
2/2008 Ocera Therapeutics Series C 0
10/2003 OsteoBiologics Venture Round 9.2M
7/2016 Torax Medical Series E 0
2/2011 VertiFlex Venture Round 14M
8/2007 Leptos Biomedical Series C 20M
6/2011 CAS Medical Systems Post-IPO Equity 15M
12/2006 Galil Medical Venture Round 52M
1/2013 AxioMed Spine Series D 0
3/2009 Atritech Venture Round 0
12/2006 Elron Ventures Post-IPO Equity 52M
9/2014 SG Biofuels Series C 11M
2/2005 AxioMed Spine Series B 18M
10/2010 AxioMed Spine Series D 0
1/2012 SG Biofuels Series B 17M
4/2009 Torax Medical Series C 15M
11/2012 Auspex Pharmaceuticals Series D 0
6/2005 Torax Medical Series B 10M
7/2005 Solstice Neurosciences Venture Round 8M
9/2010 Celator Pharmaceuticals Series D 0
7/2006 Ocera Therapeutics Series B 12M
10/2010 Auspex Pharmaceuticals Series C 12M
1/2014 Auspex Pharmaceuticals Series E 0
8/2006 Zogenix Series A 60M
9/2010 Cebix Venture Round 16M
10/2012 Cebix Series B 0
10/2014 Invitae Series F 0
11/2007 Clarus Therapeutics Series C 8M
9/2004 Coley Pharmaceutical Group Series G 25.2M
11/2009 Virdante Pharmaceuticals Series A 30M
5/2010 Ntprx Series B 43M
1/2010 Intuity Medical Series D 64M
1/2004 Intuity Medical Series B 0
9/2012 Torax Medical Series D 0
11/2006 Solstice Neurosciences Series B 85M
11/2006 Quinnova Pharmaceuticals Series A 13.6M
5/2005 Tranzyme Series A -
12/2011 InnoPharma Series A 15M
8/2006 Intuity Medical Series C 20M
3/2017 VertiFlex Venture Round 0
7/2016 Torax Medical Series E 0
10/2014 Invitae Series F 0
9/2014 SG Biofuels Series C 0
1/2014 Auspex Pharmaceuticals Series E 0
1/2013 AxioMed Spine Series D 0
11/2012 Auspex Pharmaceuticals Series D 0
10/2012 Cebix Series B 0
9/2012 Torax Medical Series D 0
4/2012 Tioga Pharmaceuticals Series B 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research